This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

CHD (AVERT trial)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • this was a randomised controlled, blinded trial with 18 months follow-up
  • 341 patients were recruited who had been recommended for percutaneous transluminal coronary angioplasty (PTCA) who had stable coronary heart disease (CHD) - 177 patients were allocated to PTCA and 164 were allocated to atorvastatin, 80 mg per day
  • patients were excluded if they had left main coronary artery disease, triple vessel disease, ejection fraction of less than 40%, or recent myocardial infarction or unstable angina. There was a 100% follow-up
  • this trial revealed that treatment with atorvastatin was at least as effective as PTCA plus usual care as a means of reducing ischaemic events in patients with stable CHD. There was evidence that PTCA offered better symptom control

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.